Please select the eligibility criteria that correspond to the clinical trial below.
Title: Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Brief Summary: Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.


Options:
A: Inclusion Criteria:

* Male and female patients with symptomatic PAH (Idiopathic, Familial, Associated PAH due to connective tissue disease, congenital heart disease, portal hypertension with liver cirrhosis, or due to anorexigen or amphetamine use)
* Treatment naive patients and patients pre-treated with an Endothelin Antagonist or a Prostacyclinanalogue (except I.V.).

Exclusion Criteria:

* All types of pulmonary hypertension except subtypes of Venice Group I specified in the inclusion criteria, severe COPD (chronic obstructive pulmonary disease), uncontrolled arterial hypertension, left heart failure.
B: Inclusion Criteria:

* Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1

Exclusion Criteria:

* Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial
C: Inclusion Criteria:

* Diagnosis of an interstitial lung disease (usual interstitial pneumonia \[UIP\], nonspecific interstitial pneumonia \[NSIP\] or sarcoidosis) with high resolution CT and a total lung capacity (TLC) ≤ 90% or scleroderma associated pulmonary arterial hypertension (PAH) with total lung capacity (TLC) ≤ 80%.
* Interstitial lung disease (ILD) must have been stable for at least 3 months (decrease in forced vital capacity (FVC)\< 10% and diffusing capacity of lung for carbon monoxide (DLco) \< 15 % in 3 months), i.e. no significant changes in pulmonary function testing and stable medication in terms of ILD (e.g., corticosteroids, immunosuppressants)
* Mean pulmonary vascular resistance (PVR) \> 400 dyne sec cm-5 or mean pulmonary arterial pressure (PAP mean) \> 30 mmHg
* Pulmonary capillary wedge pressure (PCWP) \< 15 mmHg
* Hemodynamic parameters at baseline (PAP, PCWP, cardiac output \[CO\], systemic mean arterial pressure \[SAP\])
* High resolution computer tomography (HRCT) (should not be older than 12 months prior start of the study)
* Heart rate \> 55 beats per minute (BPM) and \< 105 BPM at rest
* Systolic blood pressure (SBP) \> 90 mmHg
* World Health Organisation (WHO) functional class II, III and IV
* 6 Minute Walking Test (6MWT) \> 100m and \< 450 m
* Stable controlled arterial hypertension according to current guidelines
* Women of childbearing potential will be included in the study if the pregnancy test is negative and combination of condoms with a safe and highly effective contraception method (hormonal contraception with implants or combined oral contraceptives, certain intra-uterine devices \[IUDs\]) is granted.

Exclusion Criteria:

* Co-medication:

  * Patients pretreated with specific medication for pulmonary arterial hypertension (PAH) like endothelin receptor antagonists, prostaglandins or phosphodiesterase type 5 (PDE 5) blockers are excluded from the trial.
  * Requirement for concomitant use of nitrates are contraindicated.
* Pre-existing clinically relevant lung disease other than ILD including.

  * Bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) with a forced expiratory volume in one second (FEV1)/FVC \<60% pred., active tuberculosis
  * Pulmonary hypertension of another WHO group (I, II, IV and V)
  * Severe congenital abnormalities of the lungs, thorax and diaphragm
  * Clinical or radiological evidence of a pulmovenoocclusive disease (PVOD)
* Systemic hemodynamics

  * Acute or severe chronic left heart failure (ejection fraction (EF) \< 50%)
  * Severe coronary artery disease (CAD; EF \< 50%); CAD patients must be asymptomatic and stable
  * Congenital or acquired valvular or myocardial disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension
* Pulmonary function

  * TLC predicted \< 30%
  * FEV1 (related to FVC) \< 60% predicted
* Blood gases at room air

  * Arterial partial carbon dioxide pressure (Pa CO2) \> 45 mmHg
  * Arterial partial oxygen pressure (Pa O2) \< 50 mmHg at O2 supply \>/= 4 L/min
* Peripheral organ function

  * Moderate or severe hepatic insufficiency (Child-Pugh Class Band C and/or total bilirubin \> 2.5 mg/dl (0.043 mmol/L); and/or hepatic transaminases \>3 upper limit normal \[ULN\])
  * Moderate or severe renal insufficiency (creatinine \> 2 mg/dl) or creatinine clearance according to Cockroft-Gault formula \< 35 mL/ min
D: Inclusion Criteria:

* Male and female patients with symptomatic pulmonary hypertension due to left ventricular diastolic dysfunction

Exclusion Criteria:

* Types of pulmonary hypertension other than group 2.2 of Dana Point Classification

Answer: B